RELMADA THERAPEUTICS, INC. Stock-Based Compensation
RELMADA THERAPEUTICS, INC. (RLMD) reported Stock-Based Compensation of $1.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $902.90K, a 73.82% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $956.19K, a 73.24% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.37M, a 64.75% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.51M, a 43.23% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $13.91M, a 53.93% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $30.18M, a 31.10% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $43.81M, a 0.87% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $44.19M, a 9.14% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 115 month | Share-based Payment Arrangement, Noncash Expense 118 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $902.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.86M 10-Q · filed 2026-08-06 | $4.23M derived: sum of 3 quarters · filed 2026-08-06 | $8.74M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $956.19K 10-Q · filed 2026-05-12 | $3.33M derived: sum of 2 quarters · filed 2026-05-12 | $7.84M derived: sum of 3 quarters · filed 2026-05-12 | $11.29M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.88M derived: sum of 2 quarters · filed 2026-03-19 | $10.33M derived: sum of 3 quarters · filed 2026-08-06 | $13.91M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $7.96M derived: sum of 2 quarters · filed 2026-08-06 | $11.53M 10-Q · filed 2025-11-13 | $18.26M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.02M 10-Q · filed 2026-08-06 | $7.93M 10-Q · filed 2025-08-07 | $13.75M derived: sum of 3 quarters · filed 2026-08-06 | $21.70M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $3.57M 10-Q · filed 2026-05-12 | $4.48M 10-Q · filed 2025-05-12 | $10.30M derived: sum of 2 quarters · filed 2026-05-12 | $18.25M derived: sum of 3 quarters · filed 2026-05-12 | $25.46M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $14.68M derived: sum of 2 quarters · filed 2026-03-19 | $21.89M derived: sum of 3 quarters · filed 2026-03-19 | $30.18M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $7.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $15.16M derived: sum of 2 quarters · filed 2025-11-13 | $23.46M 10-Q · filed 2025-11-13 | $33.35M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $15.51M 10-Q · filed 2025-08-07 | $25.40M derived: sum of 3 quarters · filed 2025-08-07 | $36.80M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $8.30M 10-Q · filed 2025-05-12 | $18.19M derived: sum of 2 quarters · filed 2025-05-12 | $29.58M derived: sum of 3 quarters · filed 2025-05-12 | $40.75M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $21.29M derived: sum of 2 quarters · filed 2025-03-27 | $32.46M derived: sum of 3 quarters · filed 2025-03-27 | $43.81M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $11.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $22.56M derived: sum of 2 quarters · filed 2024-11-07 | $33.92M 10-Q · filed 2024-11-07 | $45.54M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $11.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $22.52M 10-Q · filed 2024-08-07 | $34.15M derived: sum of 3 quarters · filed 2024-08-07 | $42.49M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $11.35M 10-Q · filed 2024-05-08 | $22.98M derived: sum of 2 quarters · filed 2024-05-08 | $31.32M derived: sum of 3 quarters · filed 2024-05-08 | $43.62M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $19.97M derived: sum of 2 quarters · filed 2024-03-19 | $32.26M derived: sum of 3 quarters · filed 2024-03-19 | $44.19M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $8.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $20.64M derived: sum of 2 quarters · filed 2023-11-08 | $32.57M 10-Q · filed 2023-11-08 | $50.93M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $12.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $24.23M 10-Q · filed 2023-08-08 | $42.59M derived: sum of 3 quarters · filed 2023-08-08 | $50.60M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $11.93M 10-Q · filed 2023-05-11 | $30.29M derived: sum of 2 quarters · filed 2023-05-11 | $38.31M derived: sum of 3 quarters · filed 2023-05-11 | $46.57M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $18.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $26.37M derived: sum of 2 quarters · filed 2023-03-23 | $34.64M derived: sum of 3 quarters · filed 2023-03-23 | $40.49M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $8.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $16.28M derived: sum of 2 quarters · filed 2022-11-10 | $22.13M 10-Q · filed 2022-11-10 | $25.32M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $14.12M 10-Q · filed 2022-08-11 | $17.31M derived: sum of 3 quarters · filed 2022-08-11 | $22.56M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $5.85M 10-Q · filed 2022-05-05 | $9.04M derived: sum of 2 quarters · filed 2022-05-05 | $14.29M derived: sum of 3 quarters · filed 2022-05-05 | $21.59M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $8.44M derived: sum of 2 quarters · filed 2022-03-25 | $15.74M derived: sum of 3 quarters · filed 2022-03-25 | $20.78M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $12.55M derived: sum of 2 quarters · filed 2021-11-12 | $17.59M 10-Q · filed 2021-11-12 | $19.20M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $12.34M 10-Q · filed 2021-08-10 | $13.95M derived: sum of 3 quarters · filed 2021-08-10 | $14.71M derived: sum of 4 quarters · filed 2021-08-10 | ||||
| 2020-03-31 | $5.04M 10-Q · filed 2021-05-12 | $6.65M derived: sum of 2 quarters · filed 2021-05-12 | $7.41M derived: sum of 3 quarters · filed 2021-05-12 | $7.81M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $1.61M derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-24 | $2.37M 10-K · filed 2021-03-24 | $2.77M derived: sum of 3 quarters · filed 2021-03-24 | $3.17M 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | $757.72K 10-Q · filed 2019-11-13 | $1.16M derived: sum of 2 quarters · filed 2020-08-12 | $1.56M 10-Q · filed 2020-11-12 | $1.82M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-06-30 | $403.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $798.15K 10-Q · filed 2020-08-12 | $1.06M derived: sum of 3 quarters · filed 2020-08-12 | $1.21M 10-K · filed 2021-03-24 | ||||
| 2019-03-31 | $394.69K 10-Q · filed 2020-05-15 | $657.74K derived: sum of 2 quarters · filed 2020-05-15 | $810.54K 10-Q · filed 2019-05-15 | $963.36K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $263.04K derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $415.84K 10-KT · filed 2020-03-26 | $568.67K derived: sum of 3 quarters · filed 2020-03-26 | $730.93K derived: sum of 4 quarters · filed 2020-03-26 | ||||
| 2018-09-30 | $152.80K 10-Q · filed 2019-11-13 | $305.63K derived: sum of 2 quarters · filed 2020-03-26 | $467.89K derived: sum of 3 quarters · filed 2020-03-26 | $601.93K derived: sum of 4 quarters · filed 2020-03-26 | ||||
| 2018-06-30 | $152.83K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $315.09K derived: sum of 2 quarters · filed 2020-03-26 | $449.13K derived: sum of 3 quarters · filed 2020-03-26 | $518.00K 10-KT · filed 2020-03-26 | ||||
| 2018-03-31 | $162.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | $296.30K derived: sum of 2 quarters · filed 2019-05-15 | $365.17K 10-Q · filed 2019-05-15 | $657.04K derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $134.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | $202.91K 10-Q · filed 2019-02-13 | $494.78K derived: sum of 3 quarters · filed 2019-02-13 | $603.34K derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-09-30 | $68.87K 10-Q · filed 2018-11-13 | $360.74K derived: sum of 2 quarters · filed 2018-11-13 | $469.30K derived: sum of 3 quarters · filed 2018-11-13 | $601.26K derived: sum of 4 quarters · filed 2018-11-13 | ||||
| 2017-06-30 | $291.87K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28 | $400.43K derived: sum of 2 quarters · filed 2018-09-28 | $532.39K derived: sum of 3 quarters · filed 2018-09-28 | $704.45K 10-K · filed 2018-09-28 | ||||
| 2017-03-31 | $108.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | $240.52K derived: sum of 2 quarters · filed 2018-05-14 | $412.58K 10-Q · filed 2018-05-14 | $567.40K derived: sum of 4 quarters · filed 2018-05-14 | ||||
| 2016-12-31 | $131.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | $304.02K 10-Q · filed 2018-02-12 | $458.84K derived: sum of 3 quarters · filed 2018-02-12 | $735.39K derived: sum of 4 quarters · filed 2018-02-12 | ||||
| 2016-09-30 | $172.06K 10-Q · filed 2017-11-14 | $326.88K derived: sum of 2 quarters · filed 2017-11-14 | $603.43K derived: sum of 3 quarters · filed 2017-11-14 | $891.14K derived: sum of 4 quarters · filed 2017-11-14 | ||||
| 2016-06-30 | $154.82K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | $431.36K derived: sum of 2 quarters · filed 2017-09-28 | $719.07K derived: sum of 3 quarters · filed 2017-09-28 | $1.00M 10-K · filed 2017-09-28 | ||||
| 2016-03-31 | $276.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | $564.25K derived: sum of 2 quarters · filed 2017-05-15 | $847.76K 10-Q · filed 2017-05-15 | $1.04M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $287.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10 | $571.21K 10-Q · filed 2017-02-10 | $768.09K derived: sum of 3 quarters · filed 2017-02-10 | $1.01M derived: sum of 4 quarters · filed 2017-02-10 | ||||
| 2015-09-30 | $283.50K 10-Q · filed 2016-11-10 | $480.38K derived: sum of 2 quarters · filed 2016-11-10 | $724.19K derived: sum of 3 quarters · filed 2016-11-10 | $922.47K derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $196.88K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | $440.69K derived: sum of 2 quarters · filed 2016-09-09 | $638.96K derived: sum of 3 quarters · filed 2016-09-09 | $796.95K 10-K · filed 2016-09-09 | ||||
| 2015-03-31 | $243.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | $442.09K derived: sum of 2 quarters · filed 2016-05-09 | $600.08K 10-Q · filed 2016-05-09 | $10.85M derived: sum of 4 quarters · filed 2016-05-09 | ||||
| 2014-12-31 | $198.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | $356.27K 10-Q · filed 2016-02-05 | $10.61M derived: sum of 3 quarters · filed 2016-02-05 | $10.68M derived: sum of 4 quarters · filed 2016-02-05 | ||||
| 2014-09-30 | $157.99K 10-Q · filed 2015-11-06 | $10.41M derived: sum of 2 quarters · filed 2015-11-06 | $10.48M derived: sum of 3 quarters · filed 2015-11-06 | $10.85M derived: sum of 4 quarters · filed 2015-11-06 | ||||
| 2014-06-30 | $10.25M derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $10.32M 10-K · filed 2015-09-11 | $10.69M derived: sum of 3 quarters · filed 2015-09-11 | $10.70M derived: sum of 4 quarters · filed 2015-09-11 | ||||
| 2014-03-31 | $65.44K 8-K · filed 2014-05-27 | $438.30K derived: sum of 2 quarters · filed 2015-02-13 | $447.78K 10-Q · filed 2015-05-15 | $485.11K 8-K · filed 2014-05-27 | ||||
| 2013-12-31 | $372.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $382.34K 10-Q · filed 2015-02-13 | $382.34K 10-K · filed 2015-09-11 | $419.68K 8-K · filed 2014-05-27 | ||||
| 2013-09-30 | $9.48K 10-Q · filed 2014-11-07 | |||||||
| 2013-03-31 | $13.39K 8-K · filed 2014-05-27 | |||||||
| 2012-12-31 | $37.34K 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |